Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Delivers First US Forteo Equivalent

Approved Teriparatide Generic Is Slated To Launch ‘In The Coming Weeks’

Executive Summary

Teva has celebrated a US nod for its generic version of Forteo, the first substitutable teriparatide rival to be approved by the US Food and Drug Administration.

You may also be interested in...

Teva Gets Investment From Royalty On Olanzapine LAI

Teva has announced a new investment from Royalty Pharma in its long-acting injectable formulation of olanzapine that is being developed for the US market with partner MedinCell.

Teva Raises Guidance Amid Generics Growth

Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.

Teva Looks To Novartis To Replace Departing Dethlefs

Teva’s commercial interests in North America will soon be under new leadership after the firm announced that Sven Dethlefs would leave the company in mid-November. The firm has looked to the branded sector for his replacement.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts